Medicamen Biotech Limited (BOM:531146)
India · Delayed Price · Currency is INR 344.10
-7.00 (-1.99%)
At close: Feb 12, 2026
Medicamen Biotech Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Operating Revenue | 1,627 | 1,603 | 1,779 | 1,404 | 1,083 | 1,107 |
Other Revenue | 71.88 | 72.21 | 14.26 | 4.58 | 71.55 | 19.94 |
| 1,699 | 1,675 | 1,793 | 1,409 | 1,154 | 1,127 | |
Revenue Growth (YoY) | -6.43% | -6.56% | 27.29% | 22.02% | 2.42% | -10.21% |
Cost of Revenue | 838.19 | 864.86 | 941.05 | 734.49 | 542.07 | 710.91 |
Gross Profit | 861.18 | 810.61 | 852.01 | 674.19 | 612.38 | 416.25 |
Selling, General & Admin | 367.93 | 353.42 | 335.17 | 218.24 | 155.56 | 95.99 |
Other Operating Expenses | 294.89 | 268.61 | 293.34 | 215.96 | 220.16 | 126.81 |
Operating Expenses | 726.29 | 692.69 | 699.44 | 497.86 | 433.43 | 248 |
Operating Income | 134.89 | 117.92 | 152.57 | 176.32 | 178.96 | 168.25 |
Interest Expense | -35.52 | -31.56 | -43.97 | -29.23 | -14.01 | -10.64 |
Interest & Investment Income | 5.07 | 5.07 | 7.24 | 7.21 | 1.35 | 1.53 |
Currency Exchange Gain (Loss) | 7.06 | 7.06 | 13.85 | 14.76 | 14.49 | 4.71 |
Other Non Operating Income (Expenses) | 0.28 | 0.28 | 0.33 | 1.29 | 0.08 | 0.01 |
EBT Excluding Unusual Items | 111.79 | 98.78 | 130.02 | 170.35 | 180.87 | 163.87 |
Gain (Loss) on Sale of Investments | - | - | - | - | 0.02 | 0.04 |
Gain (Loss) on Sale of Assets | - | - | 0 | -0.07 | -0.01 | -0.01 |
Pretax Income | 111.81 | 98.8 | 130.76 | 170.45 | 180.95 | 163.94 |
Income Tax Expense | 26.81 | 33.24 | 35.82 | 23.17 | 31.97 | 42.65 |
Earnings From Continuing Operations | 85.01 | 65.56 | 94.94 | 147.29 | 148.98 | 121.29 |
Minority Interest in Earnings | 5.53 | 5.53 | 14.37 | 1.16 | - | - |
Net Income | 90.53 | 71.08 | 109.31 | 148.44 | 148.98 | 121.29 |
Net Income to Common | 90.53 | 71.08 | 109.31 | 148.44 | 148.98 | 121.29 |
Net Income Growth | 19.71% | -34.97% | -26.36% | -0.36% | 22.82% | -8.74% |
Shares Outstanding (Basic) | 12 | 13 | 13 | 13 | 12 | 12 |
Shares Outstanding (Diluted) | 12 | 13 | 13 | 13 | 12 | 12 |
Shares Change (YoY) | -15.53% | 0.44% | 0.07% | 3.56% | - | 0.56% |
EPS (Basic) | 7.45 | 5.59 | 8.63 | 11.73 | 12.19 | 9.93 |
EPS (Diluted) | 7.45 | 5.59 | 8.63 | 11.73 | 12.19 | 9.93 |
EPS Growth | 41.72% | -35.25% | -26.41% | -3.78% | 22.82% | -9.24% |
Free Cash Flow | -151.89 | -103.47 | -130.31 | -128.94 | -44.99 | -51.94 |
Free Cash Flow Per Share | -12.50 | -8.14 | -10.29 | -10.19 | -3.68 | -4.25 |
Dividend Per Share | 1.000 | 1.000 | 1.000 | 1.000 | 1.000 | 1.000 |
Dividend Growth | - | - | - | - | - | 100.00% |
Gross Margin | 50.68% | 48.38% | 47.52% | 47.86% | 53.04% | 36.93% |
Operating Margin | 7.94% | 7.04% | 8.51% | 12.52% | 15.50% | 14.93% |
Profit Margin | 5.33% | 4.24% | 6.10% | 10.54% | 12.90% | 10.76% |
Free Cash Flow Margin | -8.94% | -6.18% | -7.27% | -9.15% | -3.90% | -4.61% |
EBITDA | 196.8 | 187.02 | 221.76 | 238.89 | 235.68 | 192.8 |
EBITDA Margin | 11.58% | 11.16% | 12.37% | 16.96% | 20.41% | 17.11% |
D&A For EBITDA | 61.91 | 69.1 | 69.19 | 62.56 | 56.72 | 24.55 |
EBIT | 134.89 | 117.92 | 152.57 | 176.32 | 178.96 | 168.25 |
EBIT Margin | 7.94% | 7.04% | 8.51% | 12.52% | 15.50% | 14.93% |
Effective Tax Rate | 23.97% | 33.65% | 27.39% | 13.59% | 17.67% | 26.01% |
Revenue as Reported | 1,712 | 1,688 | 1,816 | 1,433 | 1,172 | 1,135 |
Advertising Expenses | - | 11.42 | 14.37 | 6.83 | 4.6 | 0.57 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.